In this issue

Jonathan Tobin: Defending the Right to a Jewish State

Heather Hale: Compliment your kids without giving them big heads

Megan Shauri: 10 ways you are ruining your own happiness

Carolyn Bigda: 8 Best Dividend Stocks for 2015

Kiplinger's Personal Finance editors: 7 Things You Didn't Know About Paying Off Student Loans

Samantha Olson: The Crucial Mistake 55% Of Parents Are Making At Their Baby's Bedtime

Densie Well, Ph.D., R.D. Open your eyes to yellow vegetables

The Kosher Gourmet by Megan Gordon With its colorful cache of purples and oranges and reds, COLLARD GREEN SLAW is a marvelous mood booster --- not to mention just downright delish
April 18, 2014

Rabbi Yonason Goldson: Clarifying one of the greatest philosophical conundrums in theology

Caroline B. Glick: The disappearance of US will

Megan Wallgren: 10 things I've learned from my teenagers

Lizette Borreli: Green Tea Boosts Brain Power, May Help Treat Dementia

John Ericson: Trying hard to be 'positive' but never succeeding? Blame Your Brain

The Kosher Gourmet by Julie Rothman Almondy, flourless torta del re (Italian king's cake), has royal roots, is simple to make, . . . but devour it because it's simply delicious

April 14, 2014

Rabbi Dr Naftali Brawer: Passover frees us from the tyranny of time

Greg Crosby: Passing Over Religion

Eric Schulzke: First degree: How America really recovered from a murder epidemic

Georgia Lee: When love is not enough: Teaching your kids about the realities of adult relationships

Cameron Huddleston: Freebies for Your Lawn and Garden

Gordon Pape: How you can tell if your financial adviser is setting you up for potential ruin

Dana Dovey: Up to 500,000 people die each year from hepatitis C-related liver disease. New Treatment Has Over 90% Success Rate

Justin Caba: Eating Watermelon Can Help Control High Blood Pressure

The Kosher Gourmet by Joshua E. London and Lou Marmon Don't dare pass over these Pesach picks for Manischewitz!

April 11, 2014

Rabbi Hillel Goldberg: Silence is much more than golden

Caroline B. Glick: Forgetting freedom at Passover

Susan Swann: How to value a child for who he is, not just what he does

Cameron Huddleston: 7 Financial Tasks You Should Tackle Right Now

Sandra Block and Lisa Gerstner: How to Profit From Your Passion

Susan Scutti: A Simple Blood Test Might Soon Diagnose Cancer

Chris Weller: Have A Slow Metabolism? Let Science Speed It Up For You

The Kosher Gourmet by Diane Rossen Worthington Whitefish Terrine: A French take on gefilte fish

April 9, 2014

Jonathan Tobin: Why Did Kerry Lie About Israeli Blame?

Samuel G. Freedman: A resolution 70 years later for a father's unsettling legacy of ashes from Dachau

Jessica Ivins: A resolution 70 years later for a father's unsettling legacy of ashes from Dachau

Kim Giles: Asking for help is not weakness

Kathy Kristof and Barbara Hoch Marcus: 7 Great Growth Israeli Stocks

Matthew Mientka: How Beans, Peas, And Chickpeas Cleanse Bad Cholesterol and Lowers Risk of Heart Disease

Sabrina Bachai: 5 At-Home Treatments For Headaches

The Kosher Gourmet by Daniel Neman Have yourself a matzo ball: The secrets bubby never told you and recipes she could have never imagined

April 8, 2014

Lori Nawyn: At Your Wit's End and Back: Finding Peace

Susan B. Garland and Rachel L. Sheedy: Strategies Married Couples Can Use to Boost Benefits

David Muhlbaum: Smart Tax Deductions Non-Itemizers Can Claim

Jill Weisenberger, M.S., R.D.N., C.D.E : Before You Lose Your Mental Edge

Dana Dovey: Coffee Drinkers Rejoice! Your Cup Of Joe Can Prevent Death From Liver Disease

Chris Weller: Electric 'Thinking Cap' Puts Your Brain Power Into High Gear

The Kosher Gourmet by Marlene Parrish A gift of hazelnuts keeps giving --- for a variety of nutty recipes: Entree, side, soup, dessert

April 4, 2014

Rabbi David Gutterman: The Word for Nothing Means Everything

Charles Krauthammer: Kerry's folly, Chapter 3

Amy Peterson: A life of love: How to build lasting relationships with your children

John Ericson: Older Women: Save Your Heart, Prevent Stroke Don't Drink Diet

John Ericson: Why 50 million Americans will still have spring allergies after taking meds

Cameron Huddleston: Best and Worst Buys of April 2014

Stacy Rapacon: Great Mutual Funds for Young Investors

Sarah Boesveld: Teacher keeps promise to mail thousands of former students letters written by their past selves

The Kosher Gourmet by Sharon Thompson Anyone can make a salad, you say. But can they make a great salad? (SECRETS, TESTED TECHNIQUES + 4 RECIPES, INCLUDING DRESSINGS)

April 2, 2014

Paul Greenberg: Death and joy in the spring

Dan Barry: Should South Carolina Jews be forced to maintain this chimney built by Germans serving the Nazis?

Mayra Bitsko: Save me! An alien took over my child's personality

Frank Clayton: Get happy: 20 scientifically proven happiness activities

Susan Scutti: It's Genetic! Obesity and the 'Carb Breakdown' Gene

Lecia Bushak: Why Hand Sanitizer May Actually Harm Your Health

Stacy Rapacon: Great Funds You Can Own for $500 or Less

Cameron Huddleston: 7 Ways to Save on Home Decor

The Kosher Gourmet by Steve Petusevsky Exploring ingredients as edible-stuffed containers (TWO RECIPES + TIPS & TECHINQUES)

Jewish World Review

Clinical trials begin this week on new cancer therapy that cured test mice

By Zo' Elizabeth Buck

Printer Friendly Version
Email this article

http://www.JewishWorldReview.com | (MCT) Clinical trials begin this week at Wake Forest University in Winston-Salem, N.C., on a cancer therapy that has completely cured the disease in every mouse tested over the past few years.

The therapy involves the transfusion of white blood cells from cancer-resistant donors into cancer patients, letting loose a uniquely qualified army of disease fighters to attack the invading tumor.

Some scientists are skeptical about the move from mice to humans, but others are excited about the possibility of success.

Dr. Zheng Cui, the lead investigator, and his team at the Wake Forest University School of Medicine announced the move to human clinical trials on Saturday at the Understanding Aging Conference in Los Angeles. The team recently won approval for human trials from the Food and Drug Administration.

"This is the first time that such aggressive cancer in mice has been eradicated like this," Cui said. "This is a very dramatic result."

The result is especially dramatic considering its discovery stemmed from a series of accidents, starting with one extraordinary mouse.

In the late 1990s, Cui and his team were using mice as experimental cancer patients for their research, injecting them with malignant cells. Within three to four weeks, as expected, all the injected mice developed tumors and died.

But in 1999, for some reason, one mouse didn't develop tumors and didn't die.

Dr. Lloyd Old of the Ludwig Institute for Cancer Research, who was collaborating in the research, later said that if Cui had been a properly trained immunologist, he would have thrown out the mouse right then. But Cui was trained as a medical doctor, and his curiosity led him to continue testing the oddball mouse, injecting it with higher and higher lethal doses of carcinogens.

No matter how many times the researchers tried to give the mouse cancer, it didn't develop a tumor, and it didn't die.

The mouse was immune to cancer.

As cautious scientists, Cui and his team decided to breed the mouse and test its offspring for cancer immunity.

"We knew that if we hadn't made a mistake, something very dramatic was happening, but we had to know we weren't making a mistake," he said.

It wasn't a mistake. Three of the mouse's seven grandchildren didn't get cancer, either. Whatever was causing the cancer resistance was built into the mouse's family genes. News of the finding created a stir.

"Our lives were suddenly overtaken by an unexpected media frenzy," Cui wrote in 2003. Headlines proclaimed a cure for cancer - albeit in mice.

"People got very excited for a reason," he said. "It was exciting. We had direct evidence for cancer immunity that we could reproduce at will. It was a very profound result, and it was not subtle. I don't think people could have overreacted."

The next step was to figure out how to transfer that cancer immunity from the special mice to mice that were dying of cancer. The solution is apparently hidden in the mice's white blood cells, which are like a tiny biological army. They are carried in the bloodstream to fight infection and disease throughout the body.

For some reason - Cui and his team don't know why - the white blood cells from the immune mice could defeat the cancer every time, whereas the other mice's white blood cells were unable to stave off the infection.

These cellular soldiers are the focus of the majority of contemporary cancer research. But most research seeks to isolate certain parts of the cells and stimulate them in test tubes, a complex process.

Cui's procedure is simple.

"We don't have to do anything to manipulate the white blood cells," Cui said. All he and his team did was transfuse the immune mouse cells into the sick mice, and the tumors melted away.

"It's like we discovered aspirin, only instead of curing headaches it's curing cancer," Cui said. "We don't know how it works exactly, but it doesn't really matter."

Rather than spend years determining the mechanisms behind the miracle, Cui thought it was more important to press forward toward clinical trials in humans.

But Cui's eagerness to move forward could lead to problems.

"Anything that seems like a miracle always runs into roadblocks in the future," said Vivek Rangnekar, a cancer researcher at the University of Kentucky. "If you don't know the mechanism behind what is going on, you will not be equipped to deal with those roadblocks. For example, they could find that the cancer builds up a resistance, and if they don't know what's going on they will not be equipped to deal with that."

As Cui moves forward, he must first find a source for the cancer-fighting white blood cells - the human equivalent of that miraculous mouse.

Next week, Cui's team will begin a search for cancer-resistant humans.

Whether people are immune to cancer is probably rooted in their genetic background.

"Some families just don't have any cancer for generations, even among heavy smokers," he said. "Chances are it is probably not because they are lucky."

These cancer-resistant people are identified by examining how well their white blood cells fight off cancer cells in a test tube. Once a set of donors is selected, the clinical trial will move into the treatment stage, harvesting white blood cells from immune people and transfusing them into cancer patients. The process will be relatively painless by contrast with current cancer treatments such as chemotherapy or radiation therapy, which often have debilitating side effects.

"It's basically a blood transfusion - a safe procedure that goes on all the time," Cui said.

Other researchers remain cautious. Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, said it was important to note that we simply won't know anything about the viability of the therapy for humans until the clinical trial begins.

"Like with everything else, we're always hopeful, but we have to temper our enthusiasm," he said.

Some scientists expressed pessimism about the clinical trials. Lab mice have such close genetics that any two members of the same strain are essentially identical twins. This is not true in humans. Some experts worry that the cancer patients' bodies will reject the donated cells from the blood transfusion, or worse, that the white blood cells, designed to identify and attack anything foreign to them, will attack the body of the patient from the inside.

Cui said he is aware that the procedure comes with risks. But, he said, the white blood cell transfusions have been used in other fields of medicine for years.

"We've minimized all the risk, especially for these first few rounds of trials," he said. "We don't know what will happen, but we hope this will cure several types of cancer and help a few people in the next months. This could be another arrow in the cancer treatment quiver."

Every weekday JewishWorldReview.com publishes what many in the media and Washington consider "must-reading". Sign up for the daily JWR update. It's free. Just click here.

Comment by clicking here.

© 2008, The News & Observer Distributed by McClatchy-Tribune Information Services